Predilife Cash Flow Conversion Efficiency
Predilife cash flow conversion efficiency. Based on the latest financial reports, Predilife (ALPRE) has a cash flow conversion efficiency ratio of 0.219x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.28 Million ≈ $-1.49 Million USD) by net assets (€-5.82 Million ≈ $-6.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Predilife (2016–2024)
Cash flow conversion efficiency of Predilife from 2016 to 2024. This chart illustrates how Predilife's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Predilife stock price for real-time trading data and today's change.
Predilife Cash Flow Conversion Ratio Explained
Predilife cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Predilife Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Predilife ranked by their cash flow conversion efficiency. Also see market value of Predilife for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Capstone Holding Corp. Common Stock
NASDAQ:CAPS
|
-0.031x |
|
Digitalist Group Oyj
HE:DIGIGR
|
0.020x |
|
Emergent Metals Corp
V:EMR
|
-0.050x |
|
Indosterling Technomedia Tbk
JK:TECH
|
-0.019x |
|
Papyrus Australia Ltd
AU:PPY
|
2.162x |
|
Addex Therapeutics Ltd
NASDAQ:ADXN
|
-0.233x |
|
Quest PharmaTech Inc
V:QPT
|
-0.002x |
|
Pensionbee Group PLC
LSE:PBEE
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Predilife (2016–2024)
The table below shows the annual cash flow conversion efficiency of Predilife from 2016 to 2024. Review financial agility of Predilife to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-4.27 Million ≈ $-4.99 Million |
€-3.72 Million ≈ $-4.35 Million |
0.872x | +110.59% |
| 2023-12-31 | €513.52K ≈ $600.36K |
€-4.23 Million ≈ $-4.94 Million |
-8.236x | -1502.63% |
| 2022-12-31 | €-5.22 Million ≈ $-6.10 Million |
€-3.07 Million ≈ $-3.58 Million |
0.587x | -75.98% |
| 2021-12-31 | €-1.57 Million ≈ $-1.83 Million |
€-3.83 Million ≈ $-4.47 Million |
2.445x | +183.67% |
| 2020-12-31 | €721.69K ≈ $843.73K |
€-2.11 Million ≈ $-2.47 Million |
-2.922x | -193.26% |
| 2019-12-31 | €-764.29K ≈ $-893.53K |
€-2.39 Million ≈ $-2.80 Million |
3.133x | -97.90% |
| 2018-12-31 | €-12.10K ≈ $-14.15K |
€-1.81 Million ≈ $-2.11 Million |
149.479x | +12560.50% |
| 2017-12-31 | €-1.29 Million ≈ $-1.51 Million |
€-1.53 Million ≈ $-1.78 Million |
1.181x | +131.59% |
| 2016-12-31 | €362.63K ≈ $423.95K |
€-1.36 Million ≈ $-1.58 Million |
-3.737x | -- |
About Predilife
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. The company provides breast cancer predictive assessment; multi-pathology predictive assessment; and the Care4Eat solution, a nutrition assessment that allows employees to take stock of their eating habits and benefit from rebalancing and personalized advice. It also offers MammoRisk, a breast cancer pred… Read more